| NCT06747468 | Avexitide for Treatment of Post-Bariatric Hypoglycemia | RECRUITING | PHASE3 | 2025-04-29 | 2026-10 | 2026-03 |
| NCT06665165 | AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis | RECRUITING | PHASE1 | 2025-04-07 | 2027-10 | 2027-02 |
| NCT06122662 | AMX0035 and Progressive Supranuclear Palsy | ACTIVE_NOT_RECRUITING | PHASE2, PHASE3 | 2023-12-21 | 2029-11-30 | 2026-04-01 |
| NCT05676034 | AMX0035 in Adult Patients With Wolfram Syndrome | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-03-03 | 2026-12-31 | 2024-07-23 |
| NCT05619783 | Extension Study Evaluating The Safety And Tolerability of AMX0035 | COMPLETED | PHASE3 | 2022-12-29 | 2024-10-30 | 2024-10-16 |
| NCT05021536 | Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-10-28 | 2026-01-01 | 2024-01-19 |
| NCT04987671 | Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS | UNKNOWN | PHASE1, PHASE2 | 2021-08-05 | 2023-09 | 2022-05-11 |
| NCT04516096 | A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS) | COMPLETED | PHASE2, PHASE3 | 2020-11-22 | 2023-01-31 | 2022-12-30 |
| NCT03533257 | Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease | COMPLETED | PHASE2 | 2018-09-14 | 2020-11-06 | 2020-10-22 |
| NCT03488524 | Open Label Extension Study of AMX0035 in Patients With ALS | COMPLETED | PHASE2 | 2018-03-29 | 2021-03-01 | 2021-03-01 |
| NCT03127514 | AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS) | COMPLETED | PHASE2 | 2017-06-22 | 2019-11-24 | 2019-09-25 |